Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in HCC with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

Season 3 - Episode 9

In this episode, sponsored by Roche, we delve into the groundbreaking findings from the IMbrave150 trial, focusing on the efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in patients with hepatocellular carcinoma (HCC) exhibiting main trunk and/or contralateral portal vein invasion. Join experts Amit Singal and Richard Finn as they break down the key results of this pivotal study, discussing the clinical implications for treatment strategies in advanced liver cancer.